Abstract
Therapeutic siRNA is a prodrug that requires Ago2-mediated site-specific hydrolysis of the sense strand before RNA interference can occur. Although this metabolic activation step was first described 15 years ago, the kinetics of this reaction, and its relationship to in vivo siRNA efficacy, remains unexplored in the literature. To provide a roadmap to address these gaps, we describe a liquid chromatography–mass spectrometry method to monitor formation of the cleaved sense-strand metabolites in a reconstituted system. In the absence of metabolite standards for quantitation, we apply an ionization efficiency correction across a panel of siRNA molecules and find that it improves in vitro–in vivo correlation in a transgenic mouse model. Finally, we lay out a case for why Michaelis-Menten kinetics will likely be inadequate for describing Ago2-mediated metabolic activation kinetics, and propose several alternative models that can be solved numerically and applied to quantitated kinetic data when it becomes available.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rock BM, Foti RS (2019) Pharmacokinetic and drug metabolism properties of novel therapeutic modalities. Drug Metab Dispos 47:1097–1099
Adams D, Gonzalez-Duarte A, O'Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21
Hoy SM (2018) Patisiran: first global approval. Drugs 78(15):1625–1631
Scott LJ (2020) Givosiran: first approval. Drugs 80:335–339
Humphreys S, Thayer M, Campbell J et al (2020) Emerging siRNA design principles and consequences for biotransformation and disposition in drug development. J Med Chem 63(12):6407–6422
Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333
Deerberg A, Willkomm S, Restle T (2013) Minimal mechanistic model of siRNA-dependent target RNA slicing by recombinant human Argonaute 2 protein. Proc Natl Acad Sci U S A 110:17850–17855
Liu J, Carmell MA, Rivas FV et al (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437–1441
Matranga C, Tomari Y, Shin C et al (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123:607–620
Sheu-Gruttadauria J, MacRae IJ (2017) Structural foundations of RNA silencing by argonaute. J Mol Biol 429:2619–2639
Leuschner PJ, Ameres SL, Kueng S et al (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 7:314–320
Nair JK, Attarwala H, Sehgal A et al (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res 45:10969–10977
Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200
Schirle NT, MacRae IJ (2012) The crystal structure of human Argonaute2. Science 336:1037–1040
Nyakas A, Blum LC, Stucki SR et al (2013) OMA and OPA—software-supported mass spectra analysis of native and modified nucleic acids. J Am Soc Mass Spectrom 24:249–256
Elkayam E, Kuhn CD, Tocilj A et al (2012) The structure of human argonaute-2 in complex with miR-20a. Cell 150:100–110
Dahal UP, Jones JP, Davis JA et al (2011) Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates. Drug Metab Dispos 39:2355–2360
Lima WF, Wu H, Nichols JG et al (2009) Binding and cleavage specificities of human Argonaute2. J Biol Chem 284:26017–26028
Hatsis P, Waters NJ, Argikar UA (2017) Implications for metabolite quantification by mass spectrometry in the absence of authentic standards. Drug Metab Dispos 45:492–496
Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209–216
Obika S, Sekine M (2018) Synthesis of therapeutic oligonucleotides. Springer, Singapore
Ostergaard ME, Yu J, Kinberger GA et al (2015) Efficient synthesis and biological evaluation of 5′-GalNAc conjugated antisense oligonucleotides. Bioconjug Chem 26:1451–1455
Abbasi A, Paragas EM, Joswig-Jones CA et al (2019) Time course of aldehyde oxidase and why it is nonlinear. Drug Metab Dispos 47:473–483
Yadav J, Paragas E, Korzekwa K et al (2020) Time-dependent enzyme inactivation: numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacol Ther 206:107449
Nagar S, Jones JP, Korzekwa K (2014) A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. Drug Metab Dispos 42:1575–1586
Fischer E (1894) Influence of configuration on the action of enzymes. J Am Chem Soc 3:2985–2993
Koshland DE (1995) The key–lock theory and the induced fit theory. Angew Chem Int Ed Engl 33:2375–2378
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Humphreys, S.C., Basiri, B., Abbasi, A., Rock, B.M. (2021). Case Study 12: Roadmap to Quantifying Ago2-Mediated siRNA Metabolic Activation Kinetics. In: Nagar, S., Argikar, U.A., Tweedie, D. (eds) Enzyme Kinetics in Drug Metabolism. Methods in Molecular Biology, vol 2342. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1554-6_31
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1554-6_31
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1553-9
Online ISBN: 978-1-0716-1554-6
eBook Packages: Springer Protocols